A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies.
Lymph node dissection
Medullary thyroid cancer
Medullary thyroid carcinoma
Neuroendocrine tumor
RET
Targeted therapy
Thyroidectomy
Journal
Surgical oncology clinics of North America
ISSN: 1558-5042
Titre abrégé: Surg Oncol Clin N Am
Pays: United States
ID NLM: 9211789
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
entrez:
16
3
2023
pubmed:
17
3
2023
medline:
21
3
2023
Statut:
ppublish
Résumé
Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that can be sporadic or inherited and is often associated with mutations in the RET (Rearranged during Transfection) oncogene. The primary treatment for MTC is surgical resection of all suspected disease, but recent advances in targeted therapies for MTC, including the selective RET inhibitors selpercatinib and pralsetinib, have led to changes in the management of patients with locally advanced, metastatic, or recurrent MTC. In this article, we review updates on the evaluation and management of patients with MTC, focusing on new and emerging therapies that are likely to improve patient outcomes.
Identifiants
pubmed: 36925182
pii: S1055-3207(22)00082-5
doi: 10.1016/j.soc.2022.10.002
pii:
doi:
Substances chimiques
Proto-Oncogene Mas
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-250Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.